146 related articles for article (PubMed ID: 28070733)
1. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
[TBL] [Abstract][Full Text] [Related]
4. Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study.
Federici MO; McQuillan J; Biricolti G; Losi S; Lebrec J; Richards C; Miglio C; Norrbacka K
Diabetes Ther; 2018 Apr; 9(2):789-801. PubMed ID: 29525885
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
6. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
11. Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus.
Lee J; Kim R; Kim MH; Lee SH; Cho JH; Lee JM; Jang SA; Kim HS
Prim Care Diabetes; 2023 Oct; 17(5):460-465. PubMed ID: 37541792
[TBL] [Abstract][Full Text] [Related]
12. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Wang J; Jin X; An P; Yu S; Mu Y
J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945
[TBL] [Abstract][Full Text] [Related]
14. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
Svensson AM; Toll A; Lebrec J; Miftaraj M; Franzén S; Eliasson B
Diabetes Obes Metab; 2021 Mar; 23(3):720-729. PubMed ID: 33289287
[TBL] [Abstract][Full Text] [Related]
17. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
19. Exenatide extended-release; clinical trials, patient preference, and economic considerations.
Doggrell SA
Patient Prefer Adherence; 2013; 7():35-45. PubMed ID: 23341736
[TBL] [Abstract][Full Text] [Related]
20. Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
Marso SP; Hardy E; Han J; Wang H; Chilton RJ
Diabetes Ther; 2018 Apr; 9(2):551-564. PubMed ID: 29397532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
